Extended Data Fig. 10: Toxicity assay results and body weight measurements of mice treated with PARP inhibitors (PARPi) and ALK inhibitors. | Nature Cancer

Extended Data Fig. 10: Toxicity assay results and body weight measurements of mice treated with PARP inhibitors (PARPi) and ALK inhibitors.

From: Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

Extended Data Fig. 10

(a) Panels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine in mice bearing PARPi-resistant tumors. Mice were treated with oral talazoparib (0.33 mg/kg) and lorlatinib (5 mg/kg), either alone or in combination, five times per week. (b, c) Body weight of mice bearing PARPi-resistant tumors. Mice were treated with oral talazoparib (0.33 mg/kg) and lorlatinib (5 mg/kg), either alone or in combination, five times per week (b), or with oral olaparib (50 mg/kg) and ceritinib (7.5 mg/kg), either alone or in combination, five times per week (c). N = 5 mice were used in each treatment group. Error bars represent the mean ± SD. Statistical analysis was carried out using the two-way ANOVA analysis with no statistical significance specified as n.s.

Source data

Back to article page